ArrowMark Colorado Holdings
ITCI icon

ArrowMark Colorado Holdings’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

ArrowMark Colorado Holdings’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,591
Closed -$24K – 455
2016
Q3 		$24K Buy
+1,591
New +$64.3K ﹤0.01% 316

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Hillhouse Investment Management
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ArrowMark Colorado Holdings's ITCI Position: Q4 2016 in Review

ArrowMark Colorado Holdings sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2016, closing a stake of 1,591 shares — an estimated $24K sold.

ArrowMark Colorado Holdings first reported a position in ITCI in Q3 2016 and held it in 1 quarter. The position peaked at $24K in Q3 2016. 129 funds tracked by Wall St. Rank hold ITCI as of Q4 2016.

  • ArrowMark Colorado Holdings reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2016 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 1,591 Intra-Cellular Therapies Inc. shares in Q4 2016, an estimated $24K.
  • ArrowMark Colorado Holdings first reported a position in Intra-Cellular Therapies Inc. in Q3 2016 and held it in 1 quarter.
  • ArrowMark Colorado Holdings's Intra-Cellular Therapies Inc. position peaked at $24K in Q3 2016.
  • 129 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2016.

Based on ArrowMark Colorado Holdings's 13F filing for Q4 2016, filed 14 Feb 2017.